In a 54-week phase 2b trial, cotadutide was associated with favorable changes in body weight, serum alanine aminotransferase (ALT) levels, and markers of hepatic steatosis and fibrosis (NAFLD Fibrosis Score—NFS and Fibrosis-4 Index—FIB-4) in patients with NASH and T2DM [87]. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.